BioBridgeX
Log inCompare quotes
CMC / Manufacturing

Packaging & Labeling CDMOs

Free for buyersNeutral vendor of record
Quick answer

Packaging and labeling is the GMP step that turns released drug product into a finished, market-ready unit: secondary packaging, label printing and application, serialization, and tamper-evident sealing. You need it once material moves toward clinical supply or commercial launch. On BioBridgeX, buyers source and compare qualified packaging and labeling CDMOs under one contract, free for buyers.

Packaging & Labeling CDMOs on BioBridgeX

We are qualifying and publishing Packaging & Labeling CDMOs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is packaging and labeling, and when do you need it?

Packaging and labeling is the GMP step that takes a released, filled drug product and turns it into the unit a patient or a clinical site actually receives. Fill-finish gives you a sealed vial, a prefilled syringe, or a blister of tablets. Packaging and labeling is everything that happens after: secondary packaging into cartons, leaflet and patient-information insertion, label printing and application, tamper-evident sealing, serialization, and the aggregation that links each saleable unit to its case and pallet. It is unglamorous work, and it is also where a surprising number of programs lose time, because the label is the last thing finalized and the first thing a regulator checks.

There are two distinct moments when you need it. The first is clinical supply, where the package is built for a trial: blinded or double-dummy presentations, randomization and kit numbers tied to an IRT or RTSM system, multi-language booklet labels for global studies, and expiry management that supports re-labeling when a stability extension comes through. The second is commercial launch and beyond, where the same product moves to high-volume runs, market-specific artwork, and full serialization and track-and-trace under the regulations of every country you sell into. The two look similar on a line but are scoped, validated, and priced very differently.

This work sits firmly under GMP, not the GLP that governs your tox studies or the GCP that governs the clinic. The container-closure you ship has to hold its sterile or stability claim, the label content has to match the approved artwork exactly, and the serialization data has to flow correctly to the right national repository. Most sponsors do not own a packaging line, so this is a CDMO purchase, often the same site that ran your fill-finish or a dedicated packaging and labeling specialist sourced separately.

What does a packaging and labeling CDMO actually do?

A packaging and labeling CDMO operates the lines and the quality system that convert bulk or primary-packaged product into released, shippable units. The exact scope depends on whether the work is clinical or commercial, and on your dosage form, but the core functions are consistent. The vendor designs and qualifies the package, runs the line under GMP, prints and applies compliant labels, handles serialization, and disposes the batch through its quality unit. For sterile product, container-closure integrity and the controls behind the sterile claim carry through this step too.

  • Secondary packaging: cartoning, blister and bottle filling for solid oral dose, kitting, leaflet and patient-information-leaflet insertion, and tamper-evident sealing.
  • Labeling: artwork management and proofing, label printing (including booklet and multi-language labels for global trials), application and verification, and controlled re-labeling when expiry is extended.
  • Serialization and aggregation: assigning unique 2D Data Matrix codes at the saleable-unit level and aggregating units to case and pallet, with data exchange to the relevant repository.
  • Track-and-trace compliance: DSCSA in the US, the EU Falsified Medicines Directive (FMD) with tamper-evidence and the EMVS, and equivalent national requirements elsewhere.
  • Clinical trial supply packaging: blinded and double-dummy presentations, randomization and kit numbering tied to IRT/RTSM, comparator sourcing and over-encapsulation, and expiry pooling.
  • Cold-chain and specialty handling: packaging qualified for 2 to 8 C or frozen product, temperature-monitor inclusion, and presentation design for devices and combination products.
  • Batch release and documentation: in-process checks, reconciliation, line clearance, and quality-unit disposition so the finished units can ship and be cited in your filing.

How do you choose a packaging and labeling CDMO?

The decision is less about headline price than about fit, compliance, and whether the vendor can hold your timeline. A packaging slot that slips pushes your launch or your first-patient-in date directly, because this step sits at the very end of the supply chain with no slack behind it. Score two or three candidates against the same written scope: your dosage form, the markets you are shipping to, your serialization and language requirements, and whether the work is clinical or commercial. The checklist below is the short version of what experienced sponsors actually verify.

Two items deserve extra weight. Serialization is the one that quietly sinks launches: confirm the vendor's level-4 system already exchanges data with the national hubs you need (the EMVS for Europe, your trading-partner setup for DSCSA) and is not a project they will build on your timeline. And artwork and label control is the most common source of recalls in this category, so ask how they manage versioning, proofing, and reconciliation, and how they handle a late label change without re-running the batch.

  • Quality and GxP status: current GMP, a clean inspection history with the agencies that matter to you (FDA, EMA, and others), and a quality unit that disposes the batch.
  • Capacity and lead time: a realistic slot, honest turnaround on the line plus artwork and serialization setup, and how they handle a re-label or a rush.
  • Modality and dosage-form fit: proven runs of your format (vial, prefilled syringe, blister, lyophilized, device or combination product) and any cold-chain or frozen handling you need.
  • Region and regulatory track record: serialization and track-and-trace compliance for every market you ship into (DSCSA, EU FMD, and national schemes), with the right multi-language labeling.
  • Data quality: serialization data exchange that connects cleanly to the national repositories, plus reconciliation and audit trails an inspector can follow.
  • IP and confidentiality: clear handling of your artwork, formulation, and supply data, and confidentiality terms that hold across a multi-vendor program.

Frequently asked questions

Is packaging and labeling a CDMO or a CRO service?
It is a CDMO service. Packaging and labeling is physical GMP manufacturing work: running lines, printing and applying labels, serializing units, and disposing the batch through a quality unit. A CRO does research and study work, which is a different thing. Many sponsors run packaging and labeling at the same CDMO that handled their fill-finish, but it is often sourced as a separate specialist, especially for clinical trial supply or for markets with their own serialization rules. On BioBridgeX you can source it under the same contract as your other CMC and supply vendors.
What is the difference between primary and secondary packaging?
Primary packaging is the container in direct contact with the drug: the vial, syringe, blister, or bottle, usually closed during fill-finish. Secondary packaging is everything around it: the carton, the patient-information leaflet, the label, the tamper-evident seal, and any kitting. Packaging and labeling as a sourced service is mostly secondary packaging plus labeling and serialization, though it can include primary packaging for solid oral dose (blistering or bottling). The distinction matters because the sterile or container-closure claim is set at the primary level, while serialization and market-specific artwork happen at the secondary level.
What does serialization involve and which regulations apply?
Serialization means assigning a unique identifier (a 2D Data Matrix carrying a product code, serial number, lot, and expiry) to each saleable unit, then aggregating those units to cases and pallets so a product can be traced through the supply chain. In the US this is required under the Drug Supply Chain Security Act (DSCSA). In the European Union it falls under the Falsified Medicines Directive (FMD), with tamper-evidence and verification through the European Medicines Verification System. Other markets run their own national schemes. Confirm a vendor's serialization system already exchanges data with the hubs you need rather than treating it as a build.
How is clinical trial packaging different from commercial packaging?
Clinical packaging is built for a trial, not a market. It typically involves blinding or double-dummy presentations, randomization and kit numbers tied to an IRT or RTSM system, multi-language booklet labels for global studies, comparator sourcing, and expiry management that supports re-labeling when stability data extends shelf life. Commercial packaging runs at far higher volume with fixed market-specific artwork and full serialization and track-and-trace. The line work looks similar, but the scope, validation, and pricing differ, so source the vendor for the stage you are actually in.
How long does packaging and labeling take, and what drives the timeline?
It varies by whether the work is clinical or commercial, your dosage form, and how many markets and languages are involved, so plan against your specific case rather than a generic number. The line run itself is often the shortest part. The real timeline drivers are artwork approval and proofing, serialization setup and data exchange, label and component lead times, and securing a slot, since packaging sits at the end of the chain with no buffer behind it. Lock the artwork and serialization workstreams early, because they cause more slippage than the physical packaging run.
Can I source packaging and labeling together with fill-finish and distribution on BioBridgeX?
Yes, and that is a common reason to use the platform. A supply program often touches a fill-finish site, a packaging and labeling vendor, a serialization data partner, and a 3PL for distribution. Through BioBridgeX you source and compare qualified vendors for each and contract once: BioBridgeX is the neutral vendor of record, so you get one contract, one purchase order, and one invoice across every vendor. The platform is free for buyers, vendors pay a flat 2 percent on a pay-when-paid basis, and coverage spans all indications and modalities.

Source Packaging & Labeling with one contract

Compare transparent quotes from qualified Packaging & Labeling CDMOs, then contract once. Free for buyers.

Compare quotes